Original from: PR Newswire
A. Menarini Diagnostics announces an exclusive Distribution Agreement with Sinocare to register, promote, distribute, and market a new Sinocare 3rd Generation Continuous Glucose Monitoring (CGM) System within reimbursed markets. This landmark agreement grants A. Menarini Diagnostics exclusive rights to introduce this health technology to more than 20 jurisdictions in Europe.
The collaboration between A. Menarini Diagnostics and Sinocare represents a significant advancement in diabetes care. Sinocare's CGM system technology provides accurate and continuous glucose monitoring.
"The partnership with A. Menarini Diagnostics is a significant milestone in our mission to make our 3rd Generation CGM Systems widely accessible to people with diabetes," stated Dr. Jiangfeng Fei, Head of CGM Business Unit, Sinocare. "We are pleased to enter into a strategic partnership with A. Menarini Diagnostics, a leader in the healthcare industry, to bring this innovative diabetes technology to a broader audience."
A. Menarini Diagnostics shares this enthusiasm for the collaboration and its potential impact on diabetes care. "Securing exclusive rights for the distribution and marketing of this Sinocare 3rd Generation CGM System across various countries aligns with our commitment to providing innovative healthcare solutions," commented Fabio Piazzalunga, General Manager and Global Head of A. Menarini Diagnostics. "We are confident that this long-term partnership will meet the growing demand for advanced diabetes care."
By leveraging its extensive network, expertise, and resources, A. Menarini Diagnostics aims to ensure that Sinocare 3rd Generation CGM Systems reach those who can benefit most from its advanced capabilities. This partnership is expected to significantly expand the availability of Sinocare's 3rd Generation CGM systems.
